08:57 AM EDT, 04/01/2025 (MT Newswires) -- Eton Pharmaceuticals ( ETON ) said Tuesday it has out-licensed commercial rights to Increlex in territories outside of the US to Esteve Pharmaceuticals.

Increlex is indicated for the treatment of growth failure in certain pediatric patients.

Financial terms were not disclosed.

Under the terms of the deal, Esteve will license non-US Increlex rights for up to 10 years and will receive an option to acquire the international rights in the future, the company said, adding it will supply the product to Esteve at a fixed transfer price.